Sustained use of nesiritide to aid in bridging to heart transplant
Key result
Sustained use of nesiritide for 11 to 35 days in four patients with end-stage heart failure awaiting transplant provided added clinical benefit without obvious tolerance.
Why the study?
Does prolonged use of nesiritide provide clinical benefit as a bridge to heart transplant in patients with end-stage heart failure?
Population
4 patients with end-stage heart failure awaiting heart transplant, maintained on continuous intravenous…
Design
Case_series
Follow-up
11-35 days
Authors
Discussion
Loading...
Member takes
Implication
May support nesiritide bridging in end-stage HF without tolerance; hypothesis-generating, requires RCTs before practice change.
Study Design
Type
Case Report (n=4)
Structured PICO
Does prolonged use of nesiritide provide clinical benefit as a bridge to heart transplant in patients with end-stage heart failure?
P
Population
4 patients with end-stage heart failure awaiting heart transplant treated with nesiritide for 11-35 days.
I
Intervention
Nesiritide (intravenous vasodilator) for prolonged periods (11-35 days)
O
Outcome
Clinical benefit and tolerance as a bridge to transplant
Prolonged use of nesiritide may be a viable strategy to bridge patients with end-stage heart failure to heart transplantation.
Cite This Study
Hill et al. (2003) conducted a case report in End-stage heart failure awaiting heart transplant (n=4). Nesiritide was evaluated on Clinical benefit and tolerance. Sustained use of nesiritide for 11 to 35 days in four patients with end-stage heart failure awaiting transplant provided added clinical benefit without obvious tolerance.